Identifying effect modifiers of systemic hydrocortisone treatment initiated 7-14 days after birth in ventilated very preterm infants on long-term outcome: secondary analysis of a randomised controlled trial

被引:0
|
作者
Halbmeijer, Nienke Marjolein [1 ,2 ]
Sonnaert, Michel [3 ]
Swarte, Renate M. [4 ]
Koopman-Esseboom, Corine [5 ]
van Stuijvenberg, Margriet [6 ]
Mulder-de Tollenaer, Susanne [7 ]
Tan, Ratna N. G. B. [8 ]
Mohns, Thilo [9 ]
Bruneel, Els [10 ]
Steiner, Katerina [11 ]
Kramer, Boris W. [12 ,13 ]
Debeer, Anne [14 ]
van Weissenbruch, Mirjam M. [2 ,15 ]
Marechal, Yoann [16 ]
Blom, Henry [17 ]
Plaskie, Katleen [18 ]
Offringa, Martin [1 ,19 ]
Merkus, Maruschka P. [20 ]
Onland, Wes [1 ,2 ]
Leemhuis, Aleid G. [1 ,2 ]
van Kaam, Anton H. [1 ,2 ]
机构
[1] Amsterdam UMC Locat Univ Amsterdam, Neonatol, POB 22700, NL-1100 DD Amsterdam, Netherlands
[2] Amsterdam Reprod & Dev, Res Inst, Amsterdam, Netherlands
[3] Univ Ziekenhuis Brussel, Neonatol, Brussels, Belgium
[4] Erasmus MC Sophia Childrens Hosp, Neonatol, Rotterdam, Netherlands
[5] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Neonatol, Utrecht, Netherlands
[6] Univ Med Ctr Groningen, Beatrix Childrens Hosp, Neonatol, Groningen, Netherlands
[7] Isala Med Ctr, Neonatol, Zwolle, Netherlands
[8] Leiden Univ, Neonatol, Med Ctr, Leiden, Netherlands
[9] Women Mother & Child Ctr, Maxima Med Ctr, Neonatol, Veldhoven, Netherlands
[10] Ziekenhuis Oost Limburg, Neonatol, Genk, Belgium
[11] Amalia Childrens Hosp, Radboudumc Inst Hlth Sci, Neonatol, Nijmegen, Netherlands
[12] Univ Western Australia, Sch Womens & Infants Hlth, Crawley, WA, Australia
[13] Neuroplast BV, Res & Dev, Maastricht, Netherlands
[14] Univ Hosp Leuven, Neonatol, Leuven, Belgium
[15] Amsterdam UMC Locat Vrije Univ Amsterdam, Neonatol, Amsterdam, Netherlands
[16] Ctr Hosp Univ Charleroi, Neonatol, Charleroi, Belgium
[17] Univ Ziekenhuis Antwerpen, Neonatol, Edegem, Belgium
[18] St Augustinus Ziekenhuis, Neonatol, Antwerp, Belgium
[19] Univ Toronto, Hosp Sick Children, Neonatol & Child Hlth Evaluat Sci, Toronto, ON, Canada
[20] Amsterdam UMC Locat Univ Amsterdam, Epidemiol & Data Sci, Amsterdam, Netherlands
关键词
Neonatology; Infant Development; Respiratory Medicine; CARE PRACTICES; MORTALITY; MORBIDITY;
D O I
10.1136/archdischild-2023-325558
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective To explore clinical effect modifiers of systemic hydrocortisone in ventilated very preterm infants for survival and neurodevelopmental outcome at 2 years' corrected age (CA). Design Secondary analysis of a randomised placebo-controlled trial. Setting Dutch and Belgian neonatal intensive care units. Patients Infants born <30 weeks' gestational age (GA), ventilator-dependent in the second week of postnatal life. Intervention Infants were randomly assigned to systemic hydrocortisone (cumulative dose 72.5 mg/kg; n=182) or placebo (n=190). Main outcome measures The composite of death or neurodevelopmental impairment (NDI) at 2 years' CA and its components. Candidate effect modifiers (GA, small for GA, respiratory index, sex, multiple births, risk of moderate/severe bronchopulmonary dysplasia or death) were analysed using regression models with interaction terms and subpopulation treatment effect pattern plots. Results The composite outcome was available in 356 (96.0%) of 371 patients (one consent withdrawn). For this outcome, treatment effect heterogeneity was seen across GA subgroups (<27 weeks: hydrocortisone (n=141) vs placebo (n=156), 54.6% vs 66.2%; OR 0.61 (95% CI 0.38 to 0.98); >= 27 weeks: hydrocortisone (n=30) vs placebo (n=31), 66.7% vs 45.2%; OR 2.43 (95% CI 0.86 to 6.85); p=0.02 for interaction). This effect was also found for the component death (<27 weeks: 20.1% vs 32.1%; OR 0.53 (95% CI 0.32 to 0.90); =27 weeks: 28.1% vs 16.1%; OR 2.04 (95% CI 0.60 to 6.95); p=0.049 for interaction) but not for the component NDI. No differential treatment effects were observed across other subgroups. Conclusion This secondary analysis suggests that in infants <27 weeks' GA, systemic hydrocortisone may improve the outcome death or NDI, mainly driven by itscomponent death. There was insufficient evidence for other selected candidate effect modifiers.
引用
收藏
页码:159 / 165
页数:7
相关论文
共 8 条
  • [1] Short-term pulmonary and systemic effects of hydrocortisone initiated 7-14 days after birth in ventilated very preterm infants: a secondary analysis of a randomised controlled trial
    Halbmeijer, Nienke M.
    Onland, Wes
    Cools, Filip
    Kroon, Andre
    van der Heide-jalving, Marja
    Dijk, Peter
    van Straaten, Henrica L. M.
    te Pas, Arjan B.
    Mohns, Thilo
    Bruneel, Els
    van Heijst, Arno F. J.
    Kramer, Boris
    Debeer, Anne
    Zonnenberg, Inge A.
    Marechal, Yoann
    Blom, Henry
    Plaskie, Katleen
    Merkus, Maruschka P.
    Offringa, Martin
    van Kaam, Anton H.
    ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION, 2023, 108 (01): : F20 - F25
  • [2] Short-term effects of systemic hydrocortisone initiated 7 to 14 days after birth in ventilated very preterm infants
    Halbmeijer, Nienke
    Onland, Wes
    Cools, Filip
    Kroon, Andre
    van der Heide-Jalving, Marja
    Dijk, Peter
    van Straaten, Henrica
    te Pas, Arjan
    Mohns, Thilo
    Bruneel, Els
    van Heijst, Arno
    Kramer, Boris
    Debeer, Anne
    Zonnenberg, Inge
    Marechal, Yoann
    Blom, Henry
    Plaskie, Katleen
    Offringa, Martin
    van Kaam, Anton
    PEDIATRIC RESEARCH, 2021, 90 (SUPPL 1) : 38 - 38
  • [3] EBNEO Commentary: Effect of systemic hydrocortisone initiated 7-14 days after birth in ventilated preterm infants on mortality and neurodevelopment at 2 years' corrected age COMMENT
    Foo, Gillian W.
    Manley, Brett J.
    Davis, Peter G.
    ACTA PAEDIATRICA, 2022, 111 (04) : 899 - 900
  • [4] Effect of Systemic Hydrocortisone Initiated 7 to 14 Days After Birth in Ventilated Preterm Infants on Mortality and Neurodevelopment at 2 Years' Corrected Age: Follow-up of a Randomized Clinical Trial
    Halbmeijer, Nienke M.
    Onland, Wes
    Cools, Filip
    Swarte, Renate
    Van der Heide-Jalving, Marja
    Merkus, Maruschka P.
    Van Kaam, Anton H.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (04): : 355 - +
  • [5] Effect of Hydrocortisone Therapy Initiated 7 to 14 Days After Birth on Mortality or Bronchopulmonary Dysplasia Among Very Preterm Infants Receiving Mechanical Ventilation A Randomized Clinical Trial
    Onland, Wes
    Cools, Filip
    Kroon, Andre
    Rademaker, Karin
    Merkus, Maruschka P.
    Dijk, Peter H.
    van Straaten, Henrica L.
    Pas, Arjan B. Te
    Mohns, Thilo
    Bruneel, Els
    van Heijst, Arno F.
    Kramer, Boris W.
    Debeer, Anne
    Zonnenberg, Inge
    Marechal, Yoann
    Blom, Henry
    Plaskie, Katleen
    Offringa, Martin
    van Kaam, Anton H.
    Nuytemans, Debbie H.
    de Loo, Moniek van
    Kemper, E. Marleen
    Vereeck, Inez
    van der Heide-Jalving, Marja
    de Kort, Ellen
    Cavartorta, Eric
    Rassart, Anne
    Eerdekens, An
    Stuijvenberg, Margriet
    Matthijsse, Rene
    de Boode, Willem
    Niemarkt, Hendrik
    van Hattum, Ilse
    Jebbink, Liesbeth Groot
    Mulder-de Tollenaer, Susanne M.
    Tan, Ratna
    Theyskens, Claire
    van Weissenbruch, Mirjam
    Dierckx, Elke
    Rigo, Vincent
    Vrijlandt, Elianne
    van der Tweel, Ingeborg
    van Baal, Caroline
    de Wildt, Saskia
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (04): : 354 - 363
  • [6] Potential effect modifiers for treatment with chiropractic manipulation versus sham manipulation for recurrent headaches in children aged 7-14 years: development of and results from a secondary analysis of a randomised clinical trial
    Lynge, Susanne
    Vach, Werner
    Dissing, Kristina Boe
    Hestbaek, Lise
    CHIROPRACTIC & MANUAL THERAPIES, 2023, 31 (01)
  • [7] Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou et al
    Bettiol, Alessandra
    Pregnolato, Francesca
    Sciascia, Savino
    Emmi, Giacomo
    Prisco, Domenico
    Meroni, Pier Luigi
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (08)
  • [8] Response to: 'Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou et al' by Bettiol et al
    Chatzidionysiou, Katerina
    Samoli, Evangelia
    Sfikakis, Petros P.
    Tektonidou, Maria G.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (08)